Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: Coagulation factor VIIa (recombinant)
Trade Name: NovoSeven
Date Designated: 09/10/2004
Orphan Designation: Treatment of bleeding episodes in patients with congenital factor VII deficiency
Orphan Designation Status: Designated/Approved
Novo Nordisk, Inc.
100 Overlook Center
Suite 200
Princeton, New Jersey 08540
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: Coagulation factor VIIa (recombinant)
Trade Name: NovoSeven
Marketing Approval Date: 07/11/2005
Approved Labeled Indication: Treatment of bleeding episodes in patients with Factor VII Deficiency
Exclusivity End Date: 07/11/2012 
Exclusivity Protected Indication* :  
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-